title: Increases in quantitative D-dimer levels correlate with progressive disease better than circulating tumor cell counts in patients with refractory prostate cancer.
abstract: Changes in quantitative D-dimer levels, circulating tumor cell (CTC) counts, and prostate-specific antigen (PSA) levels were measured in 28 patients with refractory castration-resistant prostate cancer to assess their concordance during the course of therapy and their relationship with risk of progressive disease. A significant correlation was identified between changes in PSA and both CTC counts and D-dimer levels (r = 0.67 and 0.58, respectively; P < .001). In addition, there was a significant correlation between changes in CTC count and D-dimer level (r = 0.62; P < .001). A significantly stronger concordance between these biomarkers was noted for increasing values (sensitivity, 72%-77.8%) compared with decreasing values (specificity, 43.8%-71.4%). Notably, increases in PSA and D-dimer levels, not CTC counts, were associated with increased risks for progressive disease (P < .024). Increases in quantitative D-dimer levels correlate with progressive disease better than CTC counts in patients with refractory prostate cancer.
authors.affiliation: Dept of Pathology, Nevada Cancer Institute, One Breakthrough Way, Las Vegas, NV 89135, USA.
authors.forename: Joseph D
authors.initials: JD
authors.lastname: Khoury
authors.forename: Dorothy M
authors.initials: DM
authors.lastname: Adcock
authors.forename: Fanny
authors.initials: F
authors.lastname: Chan
authors.forename: James T
authors.initials: JT
authors.lastname: Symanowski
authors.forename: Stefan
authors.initials: S
authors.lastname: Tiefenbacher
authors.forename: Oscar
authors.initials: O
authors.lastname: Goodman
authors.forename: Lazara
authors.initials: L
authors.lastname: Paz
authors.forename: Yupo
authors.initials: Y
authors.lastname: Ma
authors.forename: David C
authors.initials: DC
authors.lastname: Ward
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Vogelzang
authors.forename: Louis M
authors.initials: LM
authors.lastname: Fink
mesh_terms: D000230:Adenocarcinoma / Q000097:blood* / Q000628:therapy; D000368:Aged; D018450:Disease Progression; D005338:Fibrin Fibrinogen Degradation Products / Q000032:analysis*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009360:Neoplastic Cells, Circulating / Q000473:pathology*; D011237:Predictive Value of Tests; D017430:Prostate-Specific Antigen / Q000097:blood; D011471:Prostatic Neoplasms / Q000097:blood* / Q000628:therapy; D017211:Treatment Failure
chemical_list: D005338:Fibrin Fibrinogen Degradation Products; C036309:fibrin fragment D; D017430:Prostate-Specific Antigen